Safety and efficacy of pembrolizumab in combination with acalabrutinib in advanced head and neck squamous cell carcinoma: Phase 2 proof-of-concept study

Matthew H Taylor
Oregon Health and Science University

Courtney B Betts
Oregon Health and Science University

Lauren Maloney
Oregon Health and Science University

Eric Nadler
Baylor University Medical Center

Alain Algazi
University of California San Francisco

See next page for additional authors

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Please let us know how this document benefits you.

Recommended Citation

Taylor, Matthew H; Betts, Courtney B; Maloney, Lauren; Nadler, Eric; Algazi, Alain; Guarino, Michael J; Nemunaitis, John; Jimeno, Antonio; Patel, Priti; Munugalavadla, Veerendra; Tao, Lin; Adkins, Douglas; Goldschmidt, Jerome H; Cohen, Ezra E W; and Coussens, Lisa M, "Safety and efficacy of pembrolizumab in combination with acalabrutinib in advanced head and neck squamous cell carcinoma: Phase 2 proof-of-concept study." Clinical cancer research. 28, 5. 903 - 914. (2022).
https://digitalcommons.wustl.edu/open_access_pubs/11625

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact vanam@wustl.edu.
Authors
Figure S2. Patient Disposition.

Enrolled
N=78

Randomized to pembrolizumab monotherapy
n=39

Received ≥1 dose of pembrolizumab monotherapy
n=39

Received pembrolizumab monotherapy throughout time on study
n=25

Discontinued study (n=25)
Death (n=16)
Study terminated by sponsor (n=7)
Withdrawal by patient (n=2)

Discontinued study (n=14)

Randomized to pembrolizumab + acalabrutinib
n=39

Received ≥1 dose of pembrolizumab + acalabrutinib
n=37

Received pembrolizumab + acalabrutinib throughout time on study
n=37

Discontinued study (n=37)
Death (n=23)
Study terminated by sponsor (n=7)
Other (n=6)
Withdrawal by patient (n=3)

Did not receive treatment (n=2)
Died before treatment (n=1)
Discontinued prior to treatment (n=1)